Folyóiratcikkek tallózása szerző szerint "Gupta N"

A találatok rendezése: Rendezés: Találatok:

  • Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma 
    Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi, Tamás; Spencer A; Hajek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG (2017)
    The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma ...
  • Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. 
    Fontebasso AM; Papillon-Cavanagh S; Schwartzentruber J; Nikbakht H; Gerges N; Fiset PO; Bechet D; Faury D; De Jay N; Ramkissoon LA; Corcoran A; Jones DT; Sturm D; Johann P; Tomita T; Goldman S; Nagib M; Bendel A; Goumnerova L; Bowers DC; Leonard JR; Rubin JB; Alden T; Browd S; Geyer JR; Leary S; Jallo G; Cohen K; Gupta N; Prados MD; Carret AS; Ellezam B; Crevier L; Klekner, Álmos; Bognár, László; Hauser, Péter; Garami, Miklós; Myseros J; Dong Z; Siegel PM; Malkin H; Ligon AH; Albrecht S; Pfister SM; Ligon KL; Majewski J; Jabado N; Kieran MW (2014)
    Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants. In 40 treatment-naive mHGAs, 39 analyzed by ...